コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ergillosis is a lethal mold infection in the immunocompromised host.
2 increasingly recognized as pathogenic in the immunocompromised host.
3 tment of this oral infection in the severely immunocompromised host.
4 atment of gastrointestinal infections in the immunocompromised host.
5 regarding gastrointestinal infections in the immunocompromised host.
6 hat causes P. carinii pneumonia (PCP) in the immunocompromised host.
7 fungal pathogen that causes pneumonia in the immunocompromised host.
8 expanded pool of EBV-infected B cells in the immunocompromised host.
9 al benefits when used for prophylaxis in the immunocompromised host.
10 thogenesis of pulmonary aspergillosis in the immunocompromised host.
11 ng cause of human disease, especially in the immunocompromised host.
12 ly contributes to disease progression in the immunocompromised host.
13 nosis and management of CMV infection in the immunocompromised host.
14 trpD mutant was essentially avirulent in an immunocompromised host.
15 e treatment of invasive aspergillosis in the immunocompromised host.
16 expressing the LMP1 deletion variant in the immunocompromised host.
17 exudative pleural effusion, especially in an immunocompromised host.
18 domain of LMP1 at the molecular level in an immunocompromised host.
19 s (HCMV) causes significant morbidity in the immunocompromised host.
20 n cause lethal invasive aspergillosis in the immunocompromised host.
21 growth advantage to intracellular Mtb in an immunocompromised host.
22 hreatening invasive fungal infections in the immunocompromised host.
23 s, resulting in a varied pathogenesis in the immunocompromised host.
24 issue source caused by Y. regensburgei in an immunocompromised host.
25 acute and chronic pulmonary infection in the immunocompromised host.
26 ife-threatening disease in the fetus and the immunocompromised host.
27 with lower respiratory tract disease in the immunocompromised host.
28 tis, keratitis, and severe infections in the immunocompromised host.
29 -threatening opportunistic infections in the immunocompromised host.
30 ns to restore virus-specific immunity in the immunocompromised host.
31 atment of gastrointestinal infections in the immunocompromised host.
32 debilitating, and difficult to treat in the immunocompromised host.
33 s against microbial infection in healthy and immunocompromised hosts.
34 edominant agent of invasive aspergillosis in immunocompromised hosts.
35 en that causes invasive pulmonary disease in immunocompromised hosts.
36 toxins or "correct" hypogammaglobulinemia in immunocompromised hosts.
37 s adherent to the epithelium in the lungs of immunocompromised hosts.
38 the immune system such as might be found in immunocompromised hosts.
39 st defense against invasive aspergillosis in immunocompromised hosts.
40 umocystis carinii causes severe pneumonia in immunocompromised hosts.
41 systems and could contribute to virulence in immunocompromised hosts.
42 n the control of gammaherpesvirus latency in immunocompromised hosts.
43 and treats EBV-driven lymphoproliferation in immunocompromised hosts.
44 better identify aberrant responses to CMV in immunocompromised hosts.
45 ng high levels of latently infected cells in immunocompromised hosts.
46 unodeficiency virus or occasionally in other immunocompromised hosts.
47 sis is a common and devastating pneumonia in immunocompromised hosts.
48 the transfer of allogeneic bone marrow into immunocompromised hosts.
49 vere infections in hospitalized patients and immunocompromised hosts.
50 r the inability to eradicate the organism in immunocompromised hosts.
51 ost microbes that cause disease primarily in immunocompromised hosts.
52 ency virus (HIV)-infected patients and other immunocompromised hosts.
53 e of morbidity and mortality in neonates and immunocompromised hosts.
54 d with several malignancies, particularly in immunocompromised hosts.
55 a fungal pathogen that causes meningitis in immunocompromised hosts.
56 ion in newborns, pregnant females, and other immunocompromised hosts.
57 ng HPV-associated malignancies in normal and immunocompromised hosts.
58 nella pneumonia, and occurs predominantly in immunocompromised hosts.
59 ng protozoan parasite of immunocompetent and immunocompromised hosts.
60 ificant source of morbidity and mortality in immunocompromised hosts.
61 ally fail to cure cryptococcal infections in immunocompromised hosts.
62 eukaryotic organism that causes pneumonia in immunocompromised hosts.
63 sed by these organisms have been reported in immunocompromised hosts.
64 mmunocompetent hosts and invasive disease in immunocompromised hosts.
65 l disease during waterborne epidemics and in immunocompromised hosts.
66 trategy for prophylaxis in vulnerable and/or immunocompromised hosts.
67 -infection-related fatalities, especially in immunocompromised hosts.
68 lance is needed to prevent CRE infections in immunocompromised hosts.
69 e of chronic respiratory tract infections in immunocompromised hosts.
70 requency in the past decade, particularly in immunocompromised hosts.
71 vidualized antifungal therapy/prophylaxis in immunocompromised hosts.
72 e range of serious infections, especially in immunocompromised hosts.
73 cause fatal disease, especially lymphoma, in immunocompromised hosts.
74 a high mortality with a rising prevalence in immunocompromised hosts.
75 y common pathogen of humans, particularly in immunocompromised hosts.
76 s of opportunistic infections in healthy and immunocompromised hosts.
77 enza viruses, especially in seriously ill or immunocompromised hosts.
78 tant CD4(+) T cells do not induce colitis in immunocompromised hosts.
79 hanced survival after adoptive transfer into immunocompromised hosts.
80 bacterium that causes systemic infections in immunocompromised hosts.
81 infections (IFI) remain a serious threat to immunocompromised hosts.
82 auses substantial morbidity and mortality in immunocompromised hosts.
83 h obstructive lung disease, and pneumonia in immunocompromised hosts.
84 pathological picture when transplanted into immunocompromised hosts.
85 gal pathogens that cause severe pneumonia in immunocompromised hosts.
86 gus, can cause lethal invasive infections in immunocompromised hosts.
87 incidence of lymphoproliferative disease in immunocompromised hosts.
88 g asthma exacerbations and severe disease in immunocompromised hosts.
89 stemic and often life-threatening disease in immunocompromised hosts.
90 e more severe and more difficult to treat in immunocompromised hosts.
91 ts also infect the gastrointestinal tract in immunocompromised hosts.
92 nary disease exacerbations, and pneumonia in immunocompromised hosts.
93 ctive immune mechanisms needed to protect an immunocompromised host against an opportunistic infectio
95 nd disseminated diseases, particularly among immunocompromised hosts and critically ill adults as wel
96 pment of antiviral resistance, especially in immunocompromised hosts and critically ill patients.
98 aeruginosa causes a variety of infections in immunocompromised hosts and in individuals with cystic f
99 g the pathogenesis of T. gondii infection in immunocompromised hosts and in the design of anti-T. gon
100 stic pathogens associated with infections in immunocompromised hosts and patients with cystic fibrosi
101 y the pathogenicity of avirulent microbes in immunocompromised hosts and the lack of pathogenicity of
102 C. albicans causes serious disease only in immunocompromised hosts and therefore the ability to imm
103 nfections are increasing, particularly among immunocompromised hosts, and a rapid diagnosis is essent
104 ajor cause of infection in normal as well as immunocompromised hosts, and the increasing prevalence o
105 xclusively in opportunistic settings--in the immunocompromised host--and these infections are the foc
107 of infection and how this is altered in the immunocompromised host are key goals for comprehension o
108 to cause a spectrum of disease states in the immunocompromised host are questions of significant biol
110 ommon microorganisms and septic arthritis in immunocompromised hosts are other noteworthy topics in t
112 luenza virus infection is complicated in the immunocompromised host because of suboptimal responses t
113 tii infection can cause diseases in not only immunocompromised hosts but also immunocompetent individ
114 umigatus causes invasive disease in severely immunocompromised hosts but is readily cleared when host
115 uses can cause high mortality, especially in immunocompromised hosts, but the impact of human metapne
119 respiratory infection in humans; however, in immunocompromised hosts, disseminated infection can occu
121 P multocida is a rare cause of infections in immunocompromised hosts, epidemiologically linked to exp
123 %) patients had no immunocompromise; 6 of 24 immunocompromised hosts had idiopathic CD4 lymphopenia,
124 wever, its role as a respiratory pathogen in immunocompromised hosts has been infrequently recognized
126 nts with HSV meningitis rapidly improve, but immunocompromised hosts have more neurologic sequelae an
127 cant morbidity, particularly in neonates and immunocompromised hosts, highlighting the need for novel
128 l known that C. neoformans generally affects immunocompromised hosts; however, C. gattii infection ca
130 us infection is an emerging challenge in the immunocompromised host, in whom it may be asymptomatic o
131 issues to consider when managing a severely immunocompromised host include the development of asympt
132 recognized as a cause of systemic illness in immunocompromised hosts, including relapsing bacteremia
133 rtant cause of life-threatening pneumonia in immunocompromised hosts, including those with AIDS.
136 f the underlying mechanisms and safety in an immunocompromised host is limited due to lack of a suita
139 nslocation across the intestinal tract in an immunocompromised host is substantially reduced after ph
140 s amebic encephalitis (GAE), an infection of immunocompromised hosts, is almost uniformly fatal.
143 ania: Leishmania superinfection is common in immunocompromised hosts, particularly those infected wit
145 e importance of considering this organism in immunocompromised hosts presenting with severe infection
146 related diseases in both immunocompetent and immunocompromised hosts, ranging from localized infectio
147 but causes various disease manifestations in immunocompromised hosts, ranging from mild mucosal infec
148 s is the result of replication in a severely immunocompromised host, rather than the direct cause of
152 a mammalian pathogen that infects and kills immunocompromised hosts such as cancer and AIDS patients
153 form (type III) commonly found in tumors of immunocompromised hosts, suggesting that immune pressure
154 ction of genetically modified cells by these immunocompromised hosts suggests that strategies to rend
155 ciated with a high oncoprotein expression in immunocompromised hosts, suggests that this part of the
156 disease, or cause more severe disease in the immunocompromised host than in the immunocompetent host.
157 is an emerging devastating infection in the immunocompromised host that is treated with corticostero
161 tant in certain patient populations, such as immunocompromised hosts, the critically ill, or individu
162 dorferi antibody had not yet appeared, or in immunocompromised hosts, the MIT compared favorably to c
166 l clinical manifestations in both normal and immunocompromised hosts; this agent is the most frequent
167 n KSHV-specific immune responses within this immunocompromised host, we implanted NOD/SCID mice with
168 investigate the interplay of viruses with an immunocompromised host, we performed functional genomics
169 hronic anemia due to persistent infection in immunocompromised hosts who cannot produce neutralizing
172 e in humans and is generally associated with immunocompromised hosts with indwelling foreign bodies.
173 diseases specific to the infected organs of immunocompromised hosts, with discontinuation of immunos
174 addition, because of an increasing number of immunocompromised hosts worldwide, the guideline address
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。